TTM
$20.47B
YoY change
+28.4%
5Y CAGR
+19.7%
Peak year (2025)
$19.83B
Cumulative EBITDA
$265.99B
EBITDA history chart for AstraZeneca (AZN) from 1990 to 2025
Latest: $19.83B
EBITDA growth chart for AstraZeneca (AZN) from 1990 to 2025
Latest: +28.4%
EBITDA history table for AstraZeneca (AZN) from 1990 to 2025
| 2025 | $19.83B | +28.4% | +$4.39B | ||
| 2024 | $15.44B | +15.0% | +$2.02B | ||
| 2023 | $13.42B | +47.7% | +$4.34B | ||
| 2022 | $9.09B | +77.7% | +$3.97B | ||
| 2021 | $5.11B | -36.8% | −$2.97B | ||
| 2020 | $8.08B | +20.4% | +$1.37B | ||
| 2019 | $6.71B | -5.6% | −$400.00M | ||
| 2018 | $7.11B | +7.4% | +$489.00M | ||
| 2017 | $6.62B | -9.0% | −$653.00M | ||
| 2016 | $7.28B | +4.5% | +$316.00M | ||
| 2015 | $6.96B | +26.8% | +$1.47B | ||
| 2014 | $5.49B | -34.2% | −$2.85B | ||
| 2013 | $8.34B | -21.9% | −$2.34B | ||
| 2012 | $10.68B | -30.6% | −$4.70B | ||
| 2011 | $15.39B | +4.4% | +$647.00M | ||
| 2010 | $14.74B | +5.7% | +$793.00M | ||
| 2009 | $13.95B | +10.5% | +$1.33B | ||
| 2008 | $12.62B | +26.8% | +$2.67B | ||
| 2007 | $9.95B | +4.1% | +$389.00M | ||
| 2006 | $9.56B | +22.1% | +$1.73B | ||
| 2005 | $7.83B | +34.6% | +$2.01B | ||
| 2004 | $5.82B | +9.7% | +$515.00M | ||
| 2003 | $5.30B | +6.7% | +$334.00M | ||
| 2002 | $4.97B | -1.0% | −$50.00M | ||
| 2001 | $5.02B | +2.1% | +$105.02M | ||
| 2000 | $4.91B | +9.2% | +$411.98M | ||
| 1999 | $4.50B | +38.5% | +$1.25B | ||
| 1998 | $3.25B | +44.7% | +$1.00B | ||
| 1997 | $2.24B | +4.4% | +$94.02M | ||
| 1996 | $2.15B | +59.1% | +$798.84M | ||
| 1995 | $1.35B | -8.5% | −$125.36M | ||
| 1994 | $1.48B | +6.0% | +$84.01M | ||
| 1993 | $1.39B | +102.8% | +$706.35M | ||
| 1992 | $687.06M | -59.1% | −$991.39M | ||
| 1991 | $1.68B | +22.2% | +$305.05M | ||
| 1990 | $1.37B | — | — |
- 2025$19.83B+28.4%
- 2024$15.44B+15.0%
- 2023$13.42B+47.7%
- 2022$9.09B+77.7%
- 2021$5.11B-36.8%
- 2020$8.08B+20.4%
- 2019$6.71B-5.6%
- 2018$7.11B+7.4%
- 2017$6.62B-9.0%
- 2016$7.28B+4.5%
- 2015$6.96B+26.8%
- 2014$5.49B-34.2%
- 2013$8.34B-21.9%
- 2012$10.68B-30.6%
- 2011$15.39B+4.4%
- 2010$14.74B+5.7%
- 2009$13.95B+10.5%
- 2008$12.62B+26.8%
- 2007$9.95B+4.1%
- 2006$9.56B+22.1%
- 2005$7.83B+34.6%
- 2004$5.82B+9.7%
- 2003$5.30B+6.7%
- 2002$4.97B-1.0%
- 2001$5.02B+2.1%
- 2000$4.91B+9.2%
- 1999$4.50B+38.5%
- 1998$3.25B+44.7%
- 1997$2.24B+4.4%
- 1996$2.15B+59.1%
- 1995$1.35B-8.5%
- 1994$1.48B+6.0%
- 1993$1.39B+102.8%
- 1992$687.06M-59.1%
- 1991$1.68B+22.2%
- 1990$1.37B—
EBITDA values are taken from AstraZeneca's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EBITDA at AstraZeneca (AZN)
According to AstraZeneca's latest reported financial statements, the company's current EBITDA (TTM) is $20.47B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
The 2025 reading of AstraZeneca (AZN) EBITDA is $19.83B – grew 28.4% year-over-year.
Through 2020–2025 (5 years), AstraZeneca EBITDA delivered a +19.7% annualised rate; sustaining 4 straight years of year-over-year growth.
Across the available history, EBITDA reached its high of $19.83B in 2025 and its low of $687.06M in 1992.
AstraZeneca EBITDA by Year
AstraZeneca EBITDA 2025: $19.83B
2025's EBITDA for AstraZeneca came in at $19.83B, grew 28.4% from 2024. This figure represents the highest annual value in the available history.
AstraZeneca EBITDA 2024: $15.44B
AstraZeneca posted EBITDA of $15.44B in 2024, grew 15.0% from 2023.
AstraZeneca EBITDA 2023: $13.42B
In 2023, AstraZeneca reported EBITDA of $13.42B, surged 47.7% from 2022.
AstraZeneca EBITDA 2022: $9.09B
AstraZeneca EBITDA in 2022 was $9.09B, surged 77.7% from 2021.
AstraZeneca EBITDA 2021: $5.11B
AstraZeneca EBITDA in 2021 was $5.11B.
See more financial history for AstraZeneca (AZN).
Sector peers by EBITDA
Healthcare peers of AstraZeneca (AZN), ranked by their latest EBITDA
| $41.05B | |
| $28.26B | |
| $27.94B | |
| $24.43B | |
| $23.06B | |
| $17.63B | |
| $16.90B | |
| $11.47B |
- $41.05B
- $28.26B
- $27.94B
- $24.43B
- $23.06B
- $17.63B
- $16.90B
Frequently asked questions
AstraZeneca (AZN) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation